The manufacturer of Otezla has a copay card for people with private or commercial insurance. This card can decrease the copay of your medication. Sometimes, you may need prior authorization from your ...

SAN FRANCISCO—When Amgen shelled out $13.4 billion late last year to pick up Celgene's blockbuster immunology med Otezla, it made a calculated guess the drug had some untapped fuel in its commercial ...

Celgene needed to sell psoriasis blockbuster Otezla to win an OK to merge with Bristol Myers Squibb, which had a potential rival in the pipeline, and Amgen stepped up with $13 billion. Now, that BMS ...

Odds are that anyone who has watched cable news of late has seen a commercial for Celgene ’s Otezla treatment for the skin condition psoriasis and psoriatic arthritis or one for its larger rival ...

Amgen Inc. AMGN announced that it has completed the previously-announced acquisition of Celgene’s blockbuster psoriasis drug Otezla, which the latter had to divest in order to complete its merger with ...

This expanded indication opens up a potential market of 1.5 million patients for Otezla. This could result in an additional $700 million in annual revenue for Amgen. Amgen offers investors a ...

Please provide your email address to receive an email when new articles are posted on . Otezla is now available in the U.S. to treat children and adolescents with moderate to severe plaque psoriasis.